196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS

Podcast: Oncology for the Inquisitive Mind · Michael Fernando and Josh Hurwitz

Opublikowano: 2026-04-09

UPDATED WITH CORRECT AUDIO While Michael daydreams of getting a haircut, this week's topics are slightly more conventional as we explore the role of more targeted agents in metastatic colorectal cancer. KRAS and BRAF mutations in colorectal cancer were historically prognostic; this has now shifted with targeted therapies available for both. In the context of metastatic colorectal cancer, BRAF mutations account for up to 10% of cases and are associated with significantly poorer overall survival compared with wild-type (WT) counterparts. The median overall survival in many cases of metastatic disease was under 15 months. Five years ago, there...